| Literature DB >> 25196834 |
Patricia I S Pinto1, Maria D Estêvão2, Deborah M Power3.
Abstract
Estrogens play well-recognized roles in reproduction across vertebrates, but also intervene in a wide range of other physiological processes, including mineral homeostasis. Classical actions are triggered when estrogens bind and activate intracellular estrogen receptors (ERs), regulating the transcription of responsive genes, but rapid non-genomic actions initiated by binding to plasma membrane receptors were recently described. A wide range of structurally diverse compounds from natural and anthropogenic sources have been shown to interact with and disrupt the normal functions of the estrogen system, and fish are particularly vulnerable to endocrine disruption, as these compounds are frequently discharged or run-off into waterways. The effect of estrogen disruptors in fish has mainly been assessed in relation to reproductive endpoints, and relatively little attention has been given to other disruptive actions. This review will overview the actions of estrogens in fish, including ER isoforms, their expression, structure and mechanisms of action. The estrogen functions will be considered in relation to mineral homeostasis and actions on mineralized tissues. The impact of estrogenic endocrine disrupting compounds on fish mineralized tissues will be reviewed, and the potential adverse outcomes of exposure to such compounds will be discussed. Current lacunae in knowledge are highlighted along with future research priorities.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25196834 PMCID: PMC4145326 DOI: 10.3390/md12084474
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Examples of the chemical structure of typical estrogenic compounds, including: (A) natural animal estrogens; (B) natural plant estrogenic compounds (phytoestrogens); and synthetic estrogenic compounds with pharmaceutical (C) or other applications (D). The compounds were selected to show the diversity of chemical structures reported to possess estrogenic effects, and compounds with reported effects in fish mineralized tissues were preferentially selected (see Section 7).
Figure 2Simplified scheme presenting the possible mechanisms involved in the cellular actions of natural estrogens (e.g., 17β-estradiol, E2) and estrogenic endocrine disrupting compounds (EDCs). In the classical mode of action (A), an estrogenic ligand binds and activates intracellular estrogen receptors (in fish, ERα, ERβa or ERβb), which dimerize in the nucleus, bind to estrogen-response elements in the promoters of target genes and regulate their transcription, through the recruitment of a range of possible cell-specific co-regulators. Alternative mechanisms of action include: (B) indirect regulation of gene expression by interaction of ligand-bound ERs with other transcription factors (TF); (C,D) estrogen actions initiated by binding to membrane receptors (ERs or G-protein coupled receptors, such as the GPER) and activation of protein kinase cascades or alterations in the levels of secondary messengers, resulting in (C) the activation of transcription factors that regulate gene expression or (D) rapid non-genomic effects, such as the activation of specific enzymes. While genomic actions can take hours to days, non-genomic effects occur in seconds or minutes. In addition, ERs can be activated and regulate gene expression in a ligand-independent manner (E) through phosphorylation (P) in response to growth factor binding to their membrane receptors. Natural estrogens may compete with several EDCs (represented by different colors and shapes) for multiple receptors and pathways, resulting in a complex response that depends on the cellular context in terms of receptors and interacting proteins and, thus, may differ between tissues and circumstances. cAMP, cyclic AMP; PKA, protein kinase A; PLC, phospholipase C; IP3, inositol 1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C. Adapted from [50].
Detection of estrogen receptor isoforms in fish mineralized tissues.
| Species | Tissue | Transcript/Protein and Detection Method | ERα | ERβa | ERβb | References |
|---|---|---|---|---|---|---|
|
| Endochondral bone (jaw) | Transcript (qRT-PCR) | √ (low) | √ | √ | [ |
|
| Dermal bone (skull) | Transcript (RT-PCR) | - | √ | √ | [ |
|
| Perichondral bone (vertebral centra) | Transcript (qRT-PCR) | √ (low) | √ | √ | [ |
|
| Chondroid bone (gill arches) | Transcript (qRT-PCR) | √ (low) | √ | √ | [ |
|
| Cartilage (Intervertebral disc) | Transcript (RT-PCR) | - | √ | √ | [ |
| Scales | Transcript (RT-PCR); Protein (IHC) | √ (low) | √ | √ | [ | |
|
| Skin with scales | Transcript (qRT-PCR) | √ (low) | √ | √ | [ |
RT-PCR, reverse transcription polymerase chain reaction; qRT-PCR, quantitative RT-PCR; IHC, immunohistochemistry; low, low level of expression.
Factors that influence the cellular response to an estrogenic EDC.
| Factor | Influence | |
|---|---|---|
| Structure of the chemical: | Determines binding to a given receptor and the resulting receptor conformation (agonist or antagonist-type) | |
| Cellular context: | Diversity and functional characteristics of receptors | The expression, sub-cellular localization and functional characteristics of intracellular ERs, their variants or membrane ERs/GPERs determine the signaling pathways that are activated or repressed |
| Diversity of coregulators | The cellular context in terms of the presence and levels of co-repressors and/or co-activators greatly influences cell-specific effects on an estrogenic ligand | |
| Diversity of other transcription factors | The diversity of other transcription factors influences the possibility of indirect actions on alternative genes | |
Selected examples of the reported effects of estrogenic disrupting compounds on fish mineralized tissues.
| Species | Compound | Effective Dose | Exposure Type and Period | Endpoint | Effect | Reference |
|---|---|---|---|---|---|---|
|
| 17α-ethynylestradiol (EE2) | 0.1 to 100 μg/L | Degree of skeletal development; spinal abnormalities | Modified skeletal developmental; vertebral malformations in up to 62% of fish | [ | |
|
| 17α-ethynylestradiol (EE2) | 1000 to 10,000 ng/L 10 and 10,000 ng/L | Skeletal and soft tissue abnormalities | Increased % of abnormal fish; increased number of abnormalities per fish | [ | |
|
| Sewage (two sewage treatment plants) | n.a. | n.a. | Hemal spines morphology | Modified hemal spines with one sewage source | [ |
|
| Bisphenol A (BPA) | 10−6 to 10−5 M | TRAP and ALP activity; transcript expression | Suppressed OSB and OSC activity; no changes in IGF-I expression | [ | |
| Tributyltin acetate (TBTA) | 10−9 to 10−5 M | TRAP and ALP activity | Inhibits OSB activity; no effect on OSC activity | [ | ||
| 3- and 4-OHBaA | 10−7 to 10−5 M | TRAP and ALP activity; transcript expression | Inhibited OSB and OSC activities 4-OHBaA down-regulated cathepsin K and IGF-I expression | [ | ||
|
| Polychlorinated biphenyl (PCB 118) | 100 ng/g BW 0.0025–2.5 ppm | TRAP and ALP activity in scales Ca level in plasma transcript expression | Increased OSC activity; hypercalcemia; increased OSC and OBS activity; upregulated cathepsin K, TRAP and RANKL expression | [ | |
|
| Raloxifene | 3.33 mg/kg BW | Ca level in plasma balance; transcript expression in dermal and perichondral bone | No change in Ca levels; downregulation of genes related to bone formation and resorption in vertebra (perichondral bone) | [ |
ALP, alkaline phosphatase; BW, body weight; dph, days post-hatch; hpf, hours post-fertilization; IGF-I, insulin-like growth factor I; OSB, osteoblasts; OSC, osteoclasts; RANKL, receptor activator of the NF-κB ligand; TRAP, tartrate-resistant acid phosphatase; 3-OHBaA, 3-hydroxybenz[a]anthracene; 4-OHBaA, 4-hydroxybenz[a]anthracene.